Camp4 Therapeutics (CAMP) Share-based Compensation (2023 - 2026)
Camp4 Therapeutics (CAMP) reported Share-based Compensation of $1.5 million for Q1 2026, up 70.96% on a YoY basis from $861000.0 in Q1 2025, and up 27.89% sequentially from $1.2 million in Q4 2025.
Camp4 Therapeutics (CAMP) Share-based Compensation (2023 - 2026) Analysis & Trends
Camp4 Therapeutics (CAMP) has 4 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 70.96% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 39.67% YoY), and the FY2025 full-year result was $4.0 million, down 0.84% from the prior year.
- Share-based Compensation rose to $1.5 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $7.2 million in Q3 2024 to a low of -$874000.0 in Q4 2023.
- A 4-year average of $1.4 million and a median of $861000.0 in 2025 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 897.23% in 2024 and plunged 86.33% in 2025, its largest moves.
- Tracing CAMP's Share-based Compensation over 4 years: stood at -$874000.0 in 2023, then surged by 191.19% to $797000.0 in 2024, then surged by 44.42% to $1.2 million in 2025, then climbed by 27.89% to $1.5 million in 2026.
- Business Quant data shows CAMP's Share-based Compensation at $1.5 million in Q1 2026, $1.2 million in Q4 2025, and $984000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Camp4 Therapeutics | 174.35 Mn | 174.35 Mn | - | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Sep 30, 2025 | 984,000.00 |
| Sep 30, 2025 | 984,000.00 |
| Jun 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 861,000.00 |
| Mar 31, 2025 | 861,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Dec 31, 2024 | 797,000.00 |
| Sep 30, 2024 | 7.20 Mn |
| Sep 30, 2024 | 7.20 Mn |
| Jun 30, 2024 | 786,000.00 |
| Jun 30, 2024 | 786,000.00 |
| Mar 31, 2024 | 856,000.00 |
| Mar 31, 2024 | 856,000.00 |
| Dec 31, 2023 | -874,000.00 |
| Dec 31, 2023 | -874,000.00 |